UK Sets Minimum Age of 11 for Puberty Blocker Trial
- Minimum age of 11 set for girls and 12 for boys
- Trial on hold due to concerns over long-term biological harms
- Medicines and Healthcare products Regulatory Agency recommended minimum age of 14
- Pathways clinical trial will not begin recruitment until issues are resolved
- Experts express concerns over long-term impact on health, sexual function, and fertility
A minimum age of 11 has been set for girls and 12 for boys for the UK puberty blocker trial. Officials said the trial is currently on hold pending resolution of concerns over long-term biological harms. The Medicines and Healthcare products Regulatory Agency had previously recommended raising the minimum age to 14 due to these concerns.
The Pathways clinical trial, which is backed by the National Institute for Health and Care Research, aims to study the effects of puberty blockers on children with gender dysphoria. However, the trial has been put on hold until the issues are resolved.
The trial's protocol states that children must have a strong desire to be a different gender than their assigned sex, a strong dislike of sexual anatomy or anticipated secondary sex characteristics, and a desire to 'transition' to live and be accepted as a person of the experienced gender.
Concerns Over Long-Term Biological Harms
The Medicines and Healthcare products Regulatory Agency had expressed concerns over the long-term biological harms of puberty blockers. Experts said that the use of these blockers can have a significant impact on a child's health, sexual function, and fertility.
Rebecca Paul MP said, 'No child can consent to the life long impact on their health, sexual function and fertility from these drugs.' She urged Andy Burnham GM to put a stop to the trial, calling it 'dangerous nonsense.'
Meanwhile, sources confirmed that discussions between the Medicines and Healthcare products Regulatory Agency and the trial sponsor, King's College London, will begin next week to discuss the wellbeing concerns.
Trial Protocol and Eligibility Criteria
The trial's protocol states that children must meet certain eligibility criteria to participate. These include having a strong desire to be a different gender than their assigned sex, a strong dislike of sexual anatomy or anticipated secondary sex characteristics, and a desire to 'transition' to live and be accepted as a person of the experienced gender.
The protocol also states that children must have a strong desire for puberty suppression for their gender incongruence and that this care preference must persist after receiving other care deemed appropriate.
However, the trial has been put on hold due to concerns over the long-term biological harms of puberty blockers. Officials said that the trial will not begin recruitment until the issues are resolved.
Context and Background
The use of puberty blockers for children with gender dysphoria has been a topic of debate in recent years. The UK has seen a significant increase in the number of children seeking treatment for gender dysphoria, with many being prescribed puberty blockers.
However, there have been concerns raised over the long-term effects of these blockers, with some experts warning that they can have a significant impact on a child's health, sexual function, and fertility.
The Pathways clinical trial aims to study the effects of puberty blockers on children with gender dysphoria and provide more information on their safety and efficacy.
Human Impact and Reactions
The decision to set a minimum age for the puberty blocker trial has been met with mixed reactions. Some have welcomed the move, saying that it will help to protect children from the potential harms of puberty blockers.
Others have expressed concern that the trial is being delayed, saying that it will deny children access to a potentially life-changing treatment.
Rebecca Paul MP has been vocal in her opposition to the trial, saying that it is 'dangerous nonsense' and that no child can consent to the long-term impact of puberty blockers on their health, sexual function, and fertility.